Francesca D’Avanzo
A5064760773- COVID-19 and healthcare impacts
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- COVID-19 Clinical Research Studies
- Effects of Radiation Exposure
- Breast Cancer Treatment Studies
- Long-Term Effects of COVID-19
- Cancer-related Molecular Pathways
- Cancer survivorship and care
- Cancer Treatment and Pharmacology
- Healthcare cost, quality, practices
- Prostate Cancer Treatment and Research
- Lipoproteins and Cardiovascular Health
- CAR-T cell therapy research
- Childhood Cancer Survivors' Quality of Life
- Chemokine receptors and signaling
- Economic and Financial Impacts of Cancer
- Extracellular vesicles in disease
- Cancer, Lipids, and Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Palliative Care and End-of-Life Issues
- Cancer Research and Treatments
- Metabolism, Diabetes, and Cancer
- Growth Hormone and Insulin-like Growth Factors
- Cancer, Stress, Anesthesia, and Immune Response
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2015-2024
Azienda Ospedaliero Universitaria Maggiore della Carita
2015-2024
Azienda Ospedaliera Ospedale Maggiore
2023
Azienda Ospedaliero-Universitaria Careggi
2022
Ospedale Maggiore
2018-2020
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2018-2020
Abstract The SARS-CoV-2 pandemic significantly affected oncology practice across the globe. There is uncertainty as to contribution of patients' demographics and oncologic features severity mortality from COVID-19 little guidance role anticancer anti–COVID-19 therapy in this population. In a multicenter study 890 patients with cancer confirmed COVID-19, we demonstrated worsening gradient breast hematologic malignancies showed that male gender, older age, number comorbidities identify subset...
PURPOSE Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared other malignancies. In absence on active therapy included in vaccination trials, a contemporary real-world evaluation outcomes during various pandemic phases, as well impact vaccination, is needed better inform clinical practice. METHODS We morbidity and among across prevaccination (February 27, 2020-November 30, 2020), Alpha-Delta (December...
Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest population. Breast cancer seem to have better prognosis when infected by SARS-CoV-2 other patients. Methods: We report a subanalysis OnCovid study providing more detailed information in breast Results: included 495 with infection. Mean age was 62.6 years; 31.5% presented one comorbidity. The most frequent subtype luminal-like ( n = 245, 49.5%) 177 (35.8%) had metastatic disease. A total 332...
559 Background: In BC, pCR is associated with substantial survival benefit. Hence, escalated neoadjuvant treatments (NATs) are being increasingly employed to improve rates, warranting biomarkers for better patients’ selection. T-cell exhaustion and senescence dysfunctional states that coexist in patients cancer, impairing antitumor immunity sustaining a suppressive immune microenvironment. Here, we assessed the impact of such on across different BC subtypes NATs. Methods: This prospective...
Background: Specialist palliative care team (SPCT) involvement has been shown to improve symptom control and end-of-life for patients with cancer, but little is known as how these have impacted by the COVID-19 pandemic. Here, we report SPCT during first wave of pandemic compare outcomes cancer who received did not receive input from multiple European centres. Methods: From OnCovid repository ( N = 1318), analysed aged ⩾18 diagnosed between 26 February 22 June 2020 had complete specialist...
e13040 Background: The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors led to a significant paradigm shift in the management Estrogen Receptor (ER) positive metastatic breast cancer (MBC). purpose this analysis was evaluate effect CDK (palbociclib, ribociclib, abemaciclib) ER MBC patients across trials terms progression free (PFS) and OS. Methods: We searched literature databases identify randomized controlled that compared endocrine therapy (ET) with ET plus CDK4/6 MBC. main...
Exposure to androgen deprivation therapy (ADT) by prostate cancer (PCa) patients is increasing, either in early-stage and metastatic disease. Frequently, ADT becomes a long-term treatment, lasting even more than 10 years, starting with gonadotropin releasing hormone (GnRH) agonists or antagonists, until the newest hormonal treatments as Abiraterone Enzalutamide. As consequence, related adverse events occurred. We reviewed medical literature using Pubmed search terms "prostate cancer",...
Abstract BackgroundEvaluation of extracellular vescicles (EVs) has been identified as a potential predictive biomarker in patients treated with IO. In particular, Glypican-1 (GPC-1), was reported to be abnormally expressed BC tissues and GPC-1+ EVs resulted significantly higher than healthy controls. Triple negative (TNBC) is characterized by poor prognosis, due the lack effective treatments; this context, Immune Checkpoint Inhibitors (ICIs) are regarded promising agents; however, their...
Background: CDK 4/6 inhibitors (palbociclib, ribociclib, abemaciclib) have been rencently introduced in the clinical management of ER positive metastatic breast cancer (MBC) patients, based on significant improvements terms progression free survival (PFS); however, no improvent overall (OS) has demonstrated individual trials so far. The purpose this analysis was to assess, across trials, effect (PFS) and combination endocrine therapy inhibitors. Methods: We searched literature databases...
e14162 Background: It is well established that an altered host metabolism has impact on cancer outcome, possibly mediated by several mechanisms, including hyperglicaemia, hyperinsulinemia and presence of chronic inflammation. The aim our analysis was to evaluate the correlation between clinical outcome in patients with advanced melanoma, kidney non-small cell lung (NSCLC), treated immune checkpoint inhibitors (anti-CTLA4, anti PD1 PDL1). Methods: relationship type 2 diabetes mellitus (DMII)...
174 Background: Despite the advent of chemotherapy and androgen-receptor signaling inhibitors (ARSi), patients with metastatic castration-resistant prostate cancer (mCRPC) still show poor prognosis reduced survival. The selective pressure induced by treatments favors activation alternative metabolic pathways that allow persistence cells in unfavorable conditions. This study aimed at assessing lipidomic profiles mCRPC, order to identify lipid species potentially useful predict for response...
Abstract Background: Increasing evidence suggests a link between T-cell senescence and tumour prognosis. In particular, high levels of circulating senescent T-lymphocytes have been also correlated with worse response to anti-cancer treatments. this perspective, therapeutic approach aimed at clearance restoring is regarded as an innovative strategy in cancer treatment currently under investigation pre-clinical clinical models. The purpose the present study characterize impact predictive...